Integra LifeSciences (NASDAQ:IART) Shares Down 3.7% – What’s Next?

Integra LifeSciences Holdings Corporation (NASDAQ:IART)’s share price fell 3.7% during mid-day trading on Thursday . The stock traded as low as $15.53 and last traded at $15.46. 124,721 shares were traded during trading, a decline of 86% from the average daily volume of 873,826 shares. The stock had previously closed at $16.06.

Analyst Upgrades and Downgrades

Several research firms have weighed in on IART. BMO Capital Markets assumed coverage on shares of Integra LifeSciences in a report on Wednesday, July 8th. They issued a “market perform” rating and a $19.00 target price on the stock. Wall Street Zen lowered shares of Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 18th. Wells Fargo & Company upped their price objective on Integra LifeSciences from $15.00 to $18.00 and gave the company an “equal weight” rating in a report on Thursday, July 30th. Truist Financial increased their price objective on Integra LifeSciences from $14.00 to $19.00 and gave the stock a “hold” rating in a research report on Thursday, July 16th. Finally, UBS Group started coverage on Integra LifeSciences in a research note on Tuesday, July 28th. They set a “neutral” rating and a $19.00 target price for the company. One research analyst has rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Integra LifeSciences has a consensus rating of “Reduce” and a consensus target price of $18.86.

Integra LifeSciences Trading Up 0.8%

The company has a debt-to-equity ratio of 1.75, a current ratio of 3.60 and a quick ratio of 2.11. The company has a market cap of $1.18 billion, a PE ratio of -169.09, a price-to-earnings-growth ratio of 0.78 and a beta of 1.21. The company’s 50 day simple moving average is $17.34 and its two-hundred day simple moving average is $14.74.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.08. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. The business had revenue of $418.76 million during the quarter, compared to analysts’ expectations of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. As a group, sell-side analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio purchased a new position in shares of Integra LifeSciences during the second quarter worth $82,000. Integrated Wealth Concepts LLC purchased a new stake in shares of Integra LifeSciences in the 2nd quarter valued at $84,000. Sequoia Financial Advisors LLC lifted its stake in Integra LifeSciences by 27.4% during the 1st quarter. Sequoia Financial Advisors LLC now owns 14,233 shares of the life sciences company’s stock worth $134,000 after acquiring an additional 3,059 shares in the last quarter. Amundi lifted its stake in Integra LifeSciences by 80.8% during the 1st quarter. Amundi now owns 19,430 shares of the life sciences company’s stock worth $183,000 after acquiring an additional 8,681 shares in the last quarter. Finally, State of Wyoming boosted its holdings in Integra LifeSciences by 26.4% during the 1st quarter. State of Wyoming now owns 25,276 shares of the life sciences company’s stock valued at $238,000 after acquiring an additional 5,278 shares during the period. 84.78% of the stock is currently owned by institutional investors and hedge funds.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery and wound care. Its technologies are designed to help healthcare professionals treat complex conditions, repair damaged tissue and support surgical procedures.

The company’s portfolio includes dural repair products and other neurosurgical implants, surgical instruments, regenerative tissue technologies, wound-care products and solutions for extremity reconstruction.